Doximity (DOCS) Cash & Equivalents (2021 - 2026)

Doximity (DOCS) has 6 years of Cash & Equivalents data on file, last reported at $219.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 4.56% year-over-year to $219.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $219.2 million (up 4.56% YoY) and the FY2026 annual result came in at $219.2 million, up 4.56% from the prior year.
• Cash & Equivalents rose to $219.2 million in Q1 2026 per DOCS's latest filing, from $64.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $306.7 million in Q2 2023 and bottomed at $64.8 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $136.5 million (2022), against an average of $146.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 81.48%; it then surged 178.61% in 2023.
• Tracing DOCS's Cash & Equivalents over 5 years: stood at $136.5 million in 2022, then retreated by 9.79% to $123.1 million in 2023, then surged by 34.27% to $165.3 million in 2024, then slumped by 60.77% to $64.8 million in 2025, then soared by 238.04% to $219.2 million in 2026.
• Per Business Quant, the three latest DOCS Cash & Equivalents figures stand at $219.2 million (Q1 2026), $64.8 million (Q4 2025), and $169.2 million (Q3 2025).

Peer Comparison